CT-155 (Boehringer Ingelheim and Click Therapeutics), an investigational prescription digital therapeutic, was both safe and effective in reducing negative symptoms of schizophrenia in a new phase 3 trial, its manufacturers announced in a press release .

Top-line results from the CONVOKE trial, which included 464 US adults with schizophrenia, showed that CT-155 plus standard-of-care antipsychotic therapy was associated with significantly reduced negative symptoms between baseline and week 16, meeting the study’s primary endpoint.

CT-155 was well tolerated and demonstrated a favorable safety profile similar to previous studies, the release said.

“The observed clinical benefit on experiential negative symptoms in this study, without additional known safety concerns, marks a critical a

See Full Page